Figure 5. CDK12-mutated prostate tumours are predicted by tandem duplications.

(a) Biallelic predictive model MSH6-d in Hartwig Medical Foundation (HMF) prostate tumours and its PR-AUC-E and area under the receiver operator characteristic (AUROC). (b) Boxplots of mutation counts between tumours that are MSH6-d loss-of-function (LOF; red) and MSH6 wild-type (grey), (mutation counts are normalised and log-transformed; Methods). (c) Biallelic predictive model for CDK12-d with performance measures (as in a). (b) Boxplots of mutation counts for CDK12-d and wild-type tumours (as in b). (e) CDK12-d predictive performance for different cancer types. Predicted probability of CDK12-d (x-axis) for tumours with CDK12 LOF (red) and CDK12 wild-type (grey) are shown for prostate cancer, breast and ovary cancer, and all other cancer types (y-axis).